DS 8500

Drug Profile

DS 8500

Alternative Names: DS-8500; DS-8500a

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperglycaemics
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2016 Daiichi Sankyo completes a phase I pharmacokinetics trial in Healthy volunteers in Japan (PO) (JapicCTI-163299)
  • 30 Nov 2016 Daiichi Sankyo completes a phase II trial in Type-2 diabetes mellitus in Japan (PO) (NCT02628392)
  • 31 Oct 2016 Daiichi Sankyo completes a phase I drug-drug interaction trial in Healthy volunteers in Japan (PO) (JapicCTI-163233)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top